Sutro Biopharma Inc (NAS:STRO)
$ 3.71 -0.05 (-1.33%) Market Cap: 303.46 Mil Enterprise Value: 18.31 Mil PE Ratio: 0 PB Ratio: 2.36 GF Score: 55/100

Sutro Biopharma Inc at Citi BioPharma Conference Transcript

Sep 06, 2023 / 12:00PM GMT
Release Date Price: $4.52 (+2.73%)
Andrew Pucher

All right. And we're live. Great. Well, good morning, everybody. My name is Andrew Pucher, I'm a Managing Director in Citi's Life Sciences Investment Banking Group. And I have the pleasure of being joined on stage here by Bill Newell, who's the CEO of Sutro Biopharma. Maybe, Bill, I could just give a quick intro and then we could get straight into it. Bill is a seasoned life sciences executive and an active industry supporter and participant at Sutro. He served as the CEO and a member of the Board since 2009. And previously was President of Aerovance, CBO at QLT and part of the executive team at Axis Pharma. Bill, thank you very much for joining us here today. First of all, good morning.

Questions & Answers

Andrew Pucher

Maybe just to start with a little bit of background. Sutro, I think, is quite a unique clinical stage biotech. You've got 2-parts to the story here. Part one is a proven ADC platform that has delivered 6 clinical trial candidates to date, including two high-value wholly-owned assets that we'll talk about today. And you also have a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot